NCT00875836

Buspirone Treatment for Marijuana Dependence

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

Conditions

• Marijuana Dependence

Interventions

Type	Name	Description
DRUG	Buspirone	Flexible dose, up to 60 mg daily
DRUG	Placebo	Flexible dose, up to 60 mg daily

Timeline

• Start date: 2009-09-01
• Primary completion: 2014-06-01
• Completion: 2016-03-01
• First posted: 2009-04-03
• Last updated: 2016-08-10
• Results posted: 2016-03-09

Locations

1 site across 1 country: United States